Cargando…

myBeST—A Web-Based Survival Prognostic Tool for Women with Breast Cancer in Malaysia: Development Process and Preliminary Validation Study

Women with breast cancer are keen to know their predicted survival. We developed a new prognostic model for women with breast cancer in Malaysia. Using the model, this study aimed to design the user interface and develop the contents of a web-based prognostic tool for the care provider to convey sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Nik Ab Kadir, Mohd Nasrullah, Mohd Hairon, Suhaily, Yaacob, Najib Majdi, Yusof, Siti Norbayah, Musa, Kamarul Imran, Yahya, Maya Mazuwin, Mohd Isa, Seoparjoo Azmel, Mamat Azlan, Muhammad Hafizuddin, Ab Hadi, Imi Sairi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966929/
https://www.ncbi.nlm.nih.gov/pubmed/36833678
http://dx.doi.org/10.3390/ijerph20042985
Descripción
Sumario:Women with breast cancer are keen to know their predicted survival. We developed a new prognostic model for women with breast cancer in Malaysia. Using the model, this study aimed to design the user interface and develop the contents of a web-based prognostic tool for the care provider to convey survival estimates. We employed an iterative website development process which includes: (1) an initial development stage informed by reviewing existing tools and deliberation among breast surgeons and epidemiologists, (2) content validation and feedback by medical specialists, and (3) face validation and end-user feedback among medical officers. Several iterative prototypes were produced and improved based on the feedback. The experts (n = 8) highly agreed on the website content and predictors for survival with content validity indices ≥ 0.88. Users (n = 20) scored face validity indices of more than 0.90. They expressed favourable responses. The tool, named Malaysian Breast cancer Survival prognostic Tool (myBeST), is accessible online. The tool estimates an individualised five-year survival prediction probability. Accompanying contents were included to explain the tool’s aim, target user, and development process. The tool could act as an additional tool to provide evidence-based and personalised breast cancer outcomes.